All these data indicate multiple roles of CD38 in MM, becoming one of the most attractive antibody targets of the immunotherapeutic approaches to inhibit MM cell growth and survival and revert immunosuppression in MM patients. The gene discussed is CD38; the disease is Miyoshi myopathy.